Ascentage Pharma Group International (NASDAQ:AAPG) Sees Strong Trading Volume – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw unusually-high trading volume on Friday . Approximately 6,325 shares traded hands during mid-day trading, an increase of 63% from the previous session’s volume of 3,885 shares.The stock last traded at $24.74 and had previously closed at $25.00.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on AAPG. Oppenheimer started coverage on Ascentage Pharma Group International in a research report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price objective on the stock. Rodman & Renshaw initiated coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price target for the company. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Piper Sandler initiated coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price objective for the company. Finally, Truist Financial set a $51.00 target price on shares of Ascentage Pharma Group International in a research note on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $48.40.

Ascentage Pharma Group International Stock Performance

The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31. The business’s fifty day moving average price is $28.36 and its two-hundred day moving average price is $34.77.

Institutional Trading of Ascentage Pharma Group International

Hedge funds have recently made changes to their positions in the business. Tema Etfs LLC acquired a new position in shares of Ascentage Pharma Group International in the second quarter valued at approximately $610,000. XY Capital Ltd lifted its holdings in Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after buying an additional 12,530 shares in the last quarter. UBS Group AG boosted its position in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares during the period. Hsbc Holdings PLC acquired a new position in shares of Ascentage Pharma Group International in the second quarter worth $391,000. Finally, Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International in the third quarter worth $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.